School of Social and Political Science

James Mittra

Job Title

Senior Lecturer and Head of Science, Technology, and Innovation Studies

Photo
James Mittra's photo

Room number

currently working from home

Building (Address)

Old Surgeons' Hall

Street (Address)

High School Yards

City (Address)

Edinburgh

Country (Address)

UK

Post code (Address)

EH1 1LZ

Background

I am currently Head of the Science, Technology and Innovation Studies Subject Group.  Previously I have been Deputy Director (Research) of the Graduate School of Social and Political Science (2015-2017); Director of the MSc in Management of Bioeconomy, Innovation and Goverance (BIG) (2014-2017) Deputy Director of the Innogen Institute (2014-2017); and Postgraduate Research Advisor (admissions) for STIS (2014-2015), when I also convened the Science, Technology and Innovation Studies Pathway for the Scottish Graduate School of Social Science.

With an undergraduate background in Humanities and Social Science, followed by postgraduate work in sociology and science and technology studies (STS), I have developed interdisciplinary research interests around innovation in life sciences, with a specific focus on translational research, regulation, and risk-governance. I have been contributing to the development of new interdisciplinary methods and theories to better understand how ‘new biology’ is affecting the nature and process of health innovation and contributing to the global bioeconomy.

Through a series of related projects following my doctoral work on the impact of genetic knowledge on the life assurance industry, I explored the nature and practical implications of translational medicine and the changing organisation and management of health R&D . With colleagues in the 
Innogen Institute, I have developed novel methods for studying business models and value systems for new technologies that do not have a conventional route to market, particularly in the field of regenerative medicine and stratified medicine.

More recently I have been exploring the concept of value (economic and non-economic aspects) in health-related innovation; particularly in the context of interdisciplinary and translational research where the distinction between public and commercial, and relationship between laboratory and clinic, has become blurred. This was written up in my first monograph: The New Health Bioeconomy: R&D Policy and Innovation for the Twenty-first century (Palgrave Macmillan, 2016).

In April 2016, I was honoured to spend a week visiting the College of the Environment and Life Sciences at the University of Rhode Island as part of its Distinguished Visiting International Scholar programme.

In 2018 I successfully completed the Edinburgh Teaching Award and became a Senior Fellow of the UK Higher Education Authority (SFHEA)

Qualifications

BA (Hons) Sociology and Philosophy (MMU 1997)

MA Sociology (University of Leeds 1998)

PhD Sociology (University of Warwick 2004)

Publications

My ORCID idenitfier is: 0000-0002-0185-6770

Books

Mittra, J. (2016) The New Health Bioeconomy: R&D Policy and Innovation for the Twenty-first Century(New York: Palgrave Macmillan)

Chapter 1 available here

Review in New Genetics and Society here

Mittra, J & C. Milne (eds) (2013) Translational Medicine: The Future of Therapy?, (Singapore: Pan-Stanford)

Journal Articles

Mittra, J., Bruce, A., Scannell, Jack W., and Tait, J. (2021) ‘The Role of the Regulatory System in Supporting Innovation Pathways for the Development of New Antimicrobial Drugs’, Technology Analysis and Strategic Management, 33 (3) 283-295

Mastroeni, M., Mittra, J., and Tait, J (2021) 'Political Influences on Biotechnology-based Innovation for European Agriculture: Risk-Assessment and Risk Management', Technology Analysis and Strategic Management, 33 (3): 271-282

Banda, G; Mittra,J., et al. (2021) 'Understanding the emergence and evolution of new business models in the UK regnerative medicine sector', Technology Analysis and Strategic Management, 33 (3): 320-333

Mittra, J., and Zoukas, G. (2020) ‘Unpacking the Concept of Bioeconomy: Problems of Definition, Measurement and the Attribution of Value’, Science and Technology Studies, 33 (1): 2-21

Mittra, J., Mastroeni, M., Haddow, G., Wield, D., and Barlow, E. (2019) ‘Re-imagining Healthcare and Medical Research Systems in Post Devolution Scotland’, Sociological Research Online, 24 (1): 55-72

Banda, G;, Tait, J;, and Mittra, J. (2018) 'Evolution of Business Models in Regenerative Medicine: Effects of a Disruptive Innovation on the Innovation Ecosystem', Clinical Therapeutics, 40 (7): 1084-1094

Wield, D., Tait., J., Chataway, J., Mittra, J., and Mastroeni, M. (2017) ‘Conceptualising and practising multiple knowledge interactions in the life sciences’, Technological Forecasting and Social Change, 116, pp. 308-315

Milne, C-P., Mittra, J., Kojima, N., Sugiyama, D., Awatin, J., and Simmons, G. (2016) 'Prospects for Harmonizing Regulatory Science Programs in Europe, Japan, and the United States to Advance Regenerative Medicine', Therapeutic Innovation and Regulatory Science, 50 (6): 724-733

Mittra. J., J. Tait., M. Mastroeni., M. Turner., J. Mountford., K. Bruce. (2015) ‘Identifying Viable Regulatory and Innovation Pathways for Regenerative Medicine: A Case Study of Cultured Red Blood Cells'New Biotechnology, 32 (1): 180-190

Mittra, J. (2013) ‘Repairing the ‘Broken Middle’ of the Health Innovation Pathway: Exploring Diverse Practitioner Perspectives on the Emergence and Role of ‘Translational Medicine’, Science and Technology Studies, 26 (3)

Wield, D., R. Hanlin, J. Mittra & J. Smith (2013) ‘Twenty-First Century Bioeconomy: Global Challenges of Biological Knowledge for Health and Agriculture’, Science and Public Policy, 40, pp. 17-24

Mittra, J & J. Tait (2012) ‘Analysing Stratified Medicine Business Models and Value Systems: Innovation-Regulation Interactions’, New Biotechnology, 29 (6), pp. 709-719

Mittra, J., J. Tait & D. Wield (2011) ‘From Maturity to High Value-Added Innovation : Lessons from the Pharmaceutical and Agro-Biotechnology Industries’, Trends in Biotechnology, 29 (3), pp. 105-109

Mittra, J., J. Tait & D. Wield (2011) ‘The Future of Pharmaceutical Innovation: New Challenges and Opportunities’, Innovations in Pharmaceutical Technology, March 2011, pp. 32-34

Mittra, J. (2008) ‘Impact of the Life Sciences on Organisation and Management of R&D in Large Pharmaceutical Firms’, Int. J. Biotechnology, 10 (5), pp. 416-440

Mittra, J. (2007) ‘Predictive Genetic Information and Access to Life Assurance: The Poverty of Genetic Exceptionalism’, Biosocieties, 2 (3), pp. 349-373

Mittra, J. (2007) ‘Marginalising Eugenic Anxiety through a Rhetoric of Liberal Choice: A Critique of the House of Commons Select Committee Report on Reproductive Technologies’, New Genetics and Society, 26 (2), pp. 159-179

Mittra, J. (2007) ‘Life Science Innovation and the Re-structuring of the Pharmaceutical Industry: Merger, Acquisitions and Strategic Alliance Behaviour of Large Firms', Technology Analysis and Strategic Management, 19 (3), pp. 279-301

Mittra, J. & R. Williams (2007) ‘Evolution of the Life Science Industries’, Technology Analysis and Strategic Management, Special Issue, 19 (3), pp. 251-255

Mittra, J. (2006) ‘The Socio-Political Economy of Pharmaceutical Mergers: A Case study of Sanofi and Aventis', Technology Analysis and Strategic Management, 18 (5), pp. 473-496

Mittra, J. (2006) ‘Genetic Exceptionalism and Precautionary Politics: Regulating for Uncertainty in Britain's Genetics and Insurance Policy Process', Science and Public Policy, 33 (8) pp. 585-600

Book Chapters

Gardner, J., Webster, A., and Mittra, J. (2017) ‘ The ‘Entrepreneurial State’ and the Leveraging of Life in the Field of Regenerative Medicine’, in Pavone, P., and Goven. J (eds) Bioeconomies: Life, Technology and Capital in the 21st Century, (Basingstoke: Palgrave Macmillan)

Milne, C.P, & J. Mittra. (2015) ‘Is Translational Medicine the Future of Therapy?’, in R. Bawa (Editor), G. F. Audette and B. E. Reese. (Assistant Editors): Handbook of Clinical Nanomedicine: Law, Business, Regulation, Safety and Risk, Pan Stanford Publishing, Singapore, pp. 997-1012

Mittra, J (2013) ‘Exploiting Translational Medicine through Public-Private Partnerships: a Case Study of Scotland’s Translational Medicine Research Collaboration (TMRC)’, In Mittra & Milne (eds) Translational Medicine: The Future of Therapy? 2013, Pan-Stanford: Singapore, pp. 213-229

Mittra, J. & C. Milne (2013) ‘Introduction to Translational Medicine’, in Mittra & Milne (eds) Translational Medicine: The Future of Therapy? 2013, Pan-Stanford: Singapore, pp. 3-13

Major Reports

Tait, J., Bruce, A., Mittra, J., Purves, J., and Scannell, J. (2014) Independent Review on Antimicrobial Resistance: Regulation-Innovation Interactions and the Development of Antimicrobial Drugs and Diagnostics for Human and Animal Diseases, Main Report for ESRC Innogen Institute

Mittra, J., M. Mastroeni & J. Tait (2014) Engaging with Uncertainty and Risk in Agricultural Biotechnology Regulation: Delivering Safety and InnovationFinal Report of ESRC/Syngenta Knowledge Exchange Project

Omidvar, O., M. De Grijs., D. Castle, J. Mittra., A. Rosiello and J. Tait (2014) Regenerative Medicine: Business Models, Venture Capital and the Funding Gap, Report on ESRC Project, ‘New Funding Models for Regenerative Medicine’ ESRC Innogen Centre/Innogen Institute

Mastroeni, M., J. Mittra & J. Tait (2012) Methodology for the Analysis of Life Science Innovation Systems (ALSIS) and its Application to Three Case StudiesFinal Report of the Technology Strategy Board (TSB) Project REALISE, May 2012

Mittra, J., & Tait, J. (2009) ‘Stem Cells’, chapter for RiskBridge Report, SAS6-CT-2006-036661, pp. 224-268

Mittra, J (2009) ‘Risk Governance and Policy Learning Within and Between Risk Fields‘, Proceedings of the RiskBridge Final Conference ECFP6 Coordination Action

Refereed Working Papers

Mittra, J., M. Mastroeni., D. Wield., E. Barlow and K. Snowden (2014) ‘The Scottish Institutional Ecology of Health and Clinical/Medical Research and Key Issues for Scottish Independence’, Innogen Working Paper Number 109,

Haddow, G., J. Mittra., K. Snowden., E. Barlow and D. Wield (2014) ‘From “Sick Man” to “Living Lab”: The Narrative of Scottish Health Since Devolution’, Innogen Working Paper, Number 108, Series ESRC Future of the UK and Scotland.

Mastroeni, M., E. Barlow., J. Mittra., and D. Wield (2014) ‘The Imagined Health Community: Narratives of Scottish Health and Independence’, Innogen Working Paper, Number 112,

Yoruk, D. and Mittra, J. (2009) 'Mid Pharma: How Big is it and Where is it Going?, Innogen Working paper 81

Mittra, J (2003) ‘Innovation Processes in Genomics Industry Sectors’, Innogen Working Paper 548

Policy Briefs/Consultation Responses

Mittra. J., E. Barlow., M. Mastroeni., D. Wield., G. Haddow (2014) ‘The Implications of Scottish Independence for Healthcare and Medical Research’, Innogen Briefing Number 2, August 2014, Series ESRC Future of the UK and Scotland.

Mittra., J (2009) Innogen Response to Human Genetics Commission Enquiry into Direct to Consumer Genetic TestsOctober 2009:

Mittra, J. (2009) Response to Nuffield Council Consultation Paper: Medical Profiling and Online Medicine: the ethics of healthcare in the molecular age, July 2009,

Mittra, J (2007) ‘Appropriate Governance of the Life Sciences: Regulation and Risk Governance of Stem Cell Therapies’, Innogen policy brief

Mittra, J. (2007) ‘Changing Strategies of Big Pharma’, Innogen Policy Brief

Tait, J, Mittra, J (2004) ‘Complexity and Innovation in the Pharmaceutical Industry’, Innogen policy brief

Other Publications

Mittra, J., G. Haddow and M. Mastroeni (2014) ‘Is Scottish Independence Bad for your Health?’ The Conversation, 12 August, 2014,

Mittra, J. (2009) ‘Translating Translational Medicine’, The Gen: The Newsletter of the ESRC Genomics Network, issue 10, p16-17.

Mittra, J. (2007) ‘GlaxoSmithKline and the Reorganization of R&D’, Innogen Case Study Prepared for Executive Development Programme, 25-27 April 2007

Mittra, J. (2007) ‘Herceptin and the Politics of Drug Regulation’, Innogen Case Study Prepared for Executive Development Programme, 25-27 April 2007

Tait, J., and Mittra, J. (2006) ‘Singing from the same Hymn Sheet: Can Genomics Harmonise with Chemistry?’ CHEManager, August, 2006, p. 14

Mittra, J. (2005) ‘Pharmaceutical Industries: Do They Prefer Treatment to Cure?’ The Biochemist 27 (3): 32-34

Tait, J. & Mittra. J. (2005) ‘Big Pharma: Coping with Complexity’, ESRC Genomics Network Newsletter, Issue 2, June 2005

Tait, J. & Mittra, J. (2004) ’Industry Challenges’, Chemistry and Industry, 6 December, 2004, No. 23, p. 24

Mittra, J. & J. Sulston (2004) ‘Genetics and Insurance: Should We Legislate?’ Genomics Network Newsletter, Issue 1, September 2004: 9-12

Research interests

Research interests

Innovation, Translational medicine, Agrobiotechnology, Pharmaceuticals, Risk governance, Regulation, Stratified medicine, Genomics, Regenerative Medicine, Value, Public-private partnerships, Collaboration, Interdiciplinarity

I use interdisciplinary methods and analytical frameworks to improve understanding of the complex and dynamic ways in which the life sciences are affecting the nature and process of technological innovation within the pharmaceutical and healthcare sectors; the emergence and development of translational research; and risk-governance issues associated with the development of regenerative medicine and other  advanced therapies.

My interests include:

  • impact of the life science and new biology on the pharmaceutical and biotechnology industries
  • new business models and value systems in the bioeconomy
  • new approaches to value and pricing in healthcare
  • translational research and collaborative approaches to R&D
  • risk governance and regulation of advanced therapies
  • genetic risk, probability and insurance
  • stakeholder engagement with science and technology

I am happy to supervise doctoral students wishing to explore these and related topics.

Completed projects

Regenerative Medicine and its Development and Implementation: An Analysis of Emergent Value Systems and Health Service Readiness (ESRC)

ESRC Independent Review on Anti-microbial Resistance

Reorganisation of Innovation in the Health Care Life Sciences

Translational Research: Conceptualising and Practicing Translation

The Future of Scottish Healthcare and Research

Engaging with Uncertainty and Risk in Agricultural Biotechnology Regulation: Delivering Safety and Innovation

A Therapy Realization Pathway Tool (TRPT) applied to three representative regenerative medicine therapeutic products (REALISE)

Innovation Processes in Life Science Industries

Riskbridge: Building Robust, Integrative Inter-disciplinary Governance Models for Emerging and Existing Risks

PhD Students

Current PhD Students

Anna Couturier (2017-) 'Mapping the Impact of Algorithms on Digital Biocitizenship: A Case Study on Mesenchymal Stromal Cell-Derived Therapies'

Kyunghoon Park (2020-) ‘Bioeconomy in Korea and Taiwan’

Rosalind Attenborough (2015-) ‘Open Science as an Identity and Epistemic Virtue’ (ESRC funded)

Completed PhD Students

Sara Valencia-Cadavid (2018) ‘Knowledge Management in the Outsourcing of Clinical Trials to Produce Vaccines in Global Alliances. Case study of Dengue Vaccine in Latin America’

David Johnson (2016) ‘Regenerative Medicine Venturing: Entrepreneurial Behaviour and New Venture Development Under High Levels of Perceived Environmental Uncertainty’ (Supervised with the Business School)

Emma King (2013):Innovation and regulation interactions in the development of clinical stem cell therapies’ (ESRC Case Student)

Donna Messner (2008): ‘Fast Track: The Transformation of Drug Approval and the Clinical Trial System for Drug Evaluation in the United States’

I am interested in supervising students on a broad range of topics in health-related innovation, policy and regulation, including new empirical and theoretical approaches to the health-related bioeconomy; innovation, risk governance and regulation of advanced therapies; value(s) and valuation practices in health innovation; understanding new R&D practices and stakeholder relations within health systems; and global challenges in areas like antimicrobial resistance.

If you are interested in being supervised by James Mittra, please see the links below (opening in new windows) for more information:

Staff Hours and Guidance

By appointment.

Publications by user content

Publication Research Explorer link
Mittra J, Zoukas G. Unpacking the concept of bioeconomy: Problems of definition, measurement, and value. Science & Technology Studies. 2020 Jan 23;33(1):2-21. https://doi.org/10.23987/sts.69662
Banda G, Tait E, Watkins A, Omdivar O, Mittra J. Understanding the emergence and evolution of new business models in the UK regenerative medicine sector. Technology Analysis and Strategic Management. 2019 Nov 13. https://doi.org/10.1080/09537325.2019.1685087
Banda G, Tait E, Mittra J. Regenerative medicine as a disruptive technology: Implications for manufacturing and clinical adoption. Cell and Gene Therapy Insights. 2019 Oct 23;5(10):1287-1303. https://doi.org/10.18609/cgti.2019.135
Mittra J, Bruce A, Scannell J, Tait J. Regulatory and market influences on innovation pathways for the development of new antimicrobial drugs. Technology Analysis and Strategic Management. 2019 Jun 23. https://doi.org/10.1080/09537325.2019.1634253
Mittra J, Mastroeni M, Haddow G, Wield D, Barlow E. Re-imagining healthcare and medical research systems in post-devolution Scotland. Sociological Research Online. 2019 Mar 11;24(1):55-72. https://doi.org/10.1177/1360780418823221
Mastroeni M, Mittra J, Tait J. Political influences on biotechnology-based innovation for European agriculture: Risk-assessment and risk management. Technology Analysis & Strategic Management. 2019 Jan 31. https://doi.org/10.1080/09537325.2019.1573983
Banda G, Tait J, Mittra J. Evolution of regenerative medicine business models: Ecosystem effects on a disruptive innovation. Clinical Therapeutics. 2018 Jul 31;40(7):1084-1094. https://doi.org/10.1016/j.clinthera.2018.06.003
Gardner J, Webster A, Mittra J. The "Entrepreneurial State" and the leveraging of life in the field of regenerative medicine. In Pavone V, Goven J, editors, Bioeconomies: Life, Technology and Capital in the 21st Century. Cham: Palgrave Macmillan. 2017. p. 25-47 https://doi.org/10.1007/978-3-319-55651-2_2
Wield D, Tait J, Chataway J, Mittra J, Mastroeni M. Conceptualising and practising multiple knowledge interactions in the life sciences. Technological Forecasting and Social Change. 2017 Mar;116:308-315. https://doi.org/10.1016/j.techfore.2016.09.025
Milne C-P, Mittra J, Kojima N, Sugiyama D, Awatin J, Simmons G. Prospects for harmonizing regulatory science programs in Europe, Japan, and the United States to advance regenerative medicine. Therapeutic Innovation & Regulatory Science. 2016 Dec 30;50(6):724-733. https://doi.org/10.1177/2168479016650716
Milne C-P, Mittra J. Is translational medicine the future of therapy? In Bawa R, Audette GF, Reese BE, editors, Handbook of Clinical Nanomedicine: Law, Business, Regulation, Safety and Risk. Pan Stanford Publishing. 2016. p. 997-1012. (Pan Stanford Series on Nanomedicine).
Mittra J. The New Health Bioeconomy: R&D Policy and Innovation for the Twenty-First Century. 1 ed. London: Palgrave Macmillan, 2015. 240 p. https://doi.org/10.1057/9781137430526
Mittra J, Tait J, Mastroeni M, Turner ML, Mountford JC, Bruce K. Identifying viable regulatory and innovation pathways for regenerative medicine: A case study of cultured red blood cells. New Biotechnology. 2015 Jan 25;32(1):180-190. https://doi.org/10.1016/j.nbt.2014.07.008
Tait E, Bruce A, Mittra J, Perves J, Scannell J. Independent Review on Anti-Microbial Resistance: Regulation-Innovation Interactions and the Development of Antimicrobial Drugs and Diagnostics for Human and Animal Diseases - Main Report. Edinburgh: Innogen Institute Report, 2014. 34 p.
Omidvar O, De Grijs M, Castle D, Mittra J, Rosiello A, Tait J. Regenerative Medicine: Business Models, Venture Capital and the Funding Gap. ESRC Innogren Centre, 2014. 40 p.
Mittra J (Author), Mastroeni M (Author), Haddow G (Author). Is Scottish Independence Bad for your Health? The Conversation. 2014.
Mittra J, Mastroeni M, Tait J. Engaging with Uncertainty and Risk in Agricultural Biotechnology Regulation: Delivering Safety and Innovation. January 2014 ed. Edinburgh: ESRC Innogren Centre, 2014. 59 p.
Haddow G, Mittra J, Snowden K, Barlow E, Wield D. From 'Sick Man' to 'Living Lab': The Narrative of Scottish Health Since Devolution. 2014. (Innogen Working Paper Series; 108).
Mittra J, Mastroeni M, Wield D, Barlow E, Snowden K. The Scottish Institutional Ecology of Health and Clinical/Medical Research and Key Issues for Scottish Independence. 2014. (Innogen Working Paper Series; 109).
Mastroeni M, Barlow E, Mittra J, Wield D. The Imagined Health Community: Narratives of Scottish Health and Independence. 2014. (Innogen Working Paper Series; 112).
Mittra J, (ed.), Milne C-P, (ed.). Translational Medicine: The Future of Therapy? Pan Stanford Publishing, 2013. 279 p.
Mittra J, Milne C-P. Introduction to Translational Medicine. In Mittra J, Milne C-P, editors, Translational Medicine: The Future of Therapy?. 1 ed. Pan Stanford Publishing. 2013. p. 3-13
Mittra J. Exploiting Translational Medicine Through Public-Private Partnerships: A Case Study of Scotland's Translational Medicine Research Collaboration (TMRC). In Mittra J, Milne C-P, editors, Translational Medicine: The Future of Therapy. Pan Stanford Publishing. 2013
Wield D, Hanlin R, Mittra J, Smith J. Twenty-First Century Bioeconomy: Global Challenges of Biological Knowledge for Health and Agriculture. Science and Public Policy. 2013;40(1):17-24. https://doi.org/10.1093/scipol/scs116
Mittra J. Repairing the 'Broken Middle' of the Health Innovation Pathway: Exploring Diverse Practitioner Perspectives on the Emergence and Role of ‘Translational Medicine’. Science & Technology Studies. 2013;26(3):103-123.
Mittra J, Tait J. Analysing Stratified Medicine Business Models and Value Systems: Innovation-Regulation Interactions. New Biotechnology. 2012 Sep;29(6):709-719. https://doi.org/10.1016/j.nbt.2012.03.003
Mastroeni M, Mittra J, Tait J. Methodology for the Analysis of Life Science Innovation Systems (ALSIS) and its Application to Three Case Studies. ESRC Innogren Centre, 2012. 51 p.
Mittra J, Tait J, Wield D. From Maturity to Value-Added Innovation: Lessons from the Pharmaceutical and Agro-Biotechnology Industries. Trends in biotechnology. 2011 Mar;29(3):105-109. https://doi.org/10.1016/j.tibtech.2010.11.004
Mittra J, Tait J, Wield D. The future of pharmaceutical innovation: New challenges and opportunities. Innovations in Pharmaceutical Technology. 2011;29(3):105-109.
Mittra J, Tait J. Stem Cells. In van der Vlies J, editor, Riskbridge Report: Coordination Action on Building Robust, Integrative inter-Disciplinary Governance models for Emerging and Existing risks. European Commission. 2009. p. 224-268
Mittra J. Impact of the Life Sciences on Organisation and Management of R and D in Large Pharmaceutical Firms. International Journal of Biotechnology. 2008;10(5):416-440. https://doi.org/10.1504/IJBT.2008.021308
Mittra J. Predictive Genetic Information and Access to Life Assurance: The Poverty of Genetic Exceptionalism. BioSocieties. 2007 Sep 1;2(3):349-373. https://doi.org/10.1017/S1745855207005789
Mittra J. Marginalising 'eugenic anxiety' through a rhetoric of 'liberal choice': a critique of the House of Commons Select Committee Report on reproductive technologies. New Genetics and Society. 2007 Aug 28;26(2):159-179. https://doi.org/10.1080/14636770701466865
Mittra J. Life Science Innovation and the Re-structuring of the Pharmaceutical Industry: Merger, Acquisitions and Strategic Alliance Behaviour of Large Firms. Technology Analysis & Strategic Management. 2007 May 16;19(3):279-301. https://doi.org/10.1080/09537320701281540
Mittra J, Williams R. Evolution of the life science industries. Technology Analysis and Strategic Management. 2007 May 1;19(3):251-255. https://doi.org/10.1080/09537320701281516
Mittra J, Williams R. Evolution of the life science industries. Technology Analysis and Strategic Management. 2007;19(3):251-255. https://doi.org/10.1080/09537320701281516
Mittra J. The Socio-Political Economy of Pharmaceutical Mergers: A Case study of Sanofi and Aventis. Technology Analysis & Strategic Management. 2006 Dec 7;18(5):473-496. https://doi.org/10.1080/09537320601019594
Mittra J. 'Genetic exceptionalism' and precautionary politics: Regulating for uncertainty in Britain's genetics and insurance policy process. Science and Public Policy. 2006 Oct;33(8):585-600.